ID Genomics

What ID Genomics does

ID Genomics is a Seattle-based molecular diagnostics company founded in 2012 that develops nucleotide sequence-based diagnostic and surveillance products targeting infectious disease pathogens and antibiotic resistance. The company's technology stack centers on two proprietary platforms: CLoNeT™, a rapid molecular diagnostic (less than 45 minutes; 25-40 minutes for the first-generation assay) that assigns proprietary barcodes to infecting bacteria by identifying fingerprint regions of bacterial DNA, and BactNeT™, a reference metadata repository linking bacterial samples, barcodes, and clinical antibiotic response data into an epidemiological surveillance database designed to track drug-resistant organism evolution. The first-generation CLoNeT™ test targets urinary tract infections and, in partnership with GroupHealth Research Institute, has demonstrated in early clinical work a reduction in antibiotic prescription errors from 25% to under 3%. Complementing these platforms is a suite of genomic services including 16S rRNA identification, 16S rRNA V3-V4-V5 metagenomics, ITS fungal profiling, MLST typing (covering up to 100 bacterial species), S. aureus SPA typing for MRSA discrimination, and Kirby-Bauer antibiotic susceptibility testing per CLSI M100S 26th Edition.

The company monetizes primarily through fee-for-service laboratory testing, accepting mail-in bacterial and SARS-CoV-2 specimens globally with next-day turnaround for samples received before noon Pacific Time. SARS-CoV-2 variant sequencing is publicly priced at $29 per sample, while other services are quote-based. A secondary revenue stream is the sale of characterized pathogenic bacterial strain collections (CRE Enterobacteriaceae, ESBL producers, MDR/XDR Pseudomonas aeruginosa, MRSA, and enterotoxigenic E. coli) to antimicrobial testing laboratories. Customer segments include healthcare providers (urgent care, hospitals) for UTI diagnostics and antibiotic stewardship, clinical and research laboratories for microbial identification and outbreak tracking, and COVID-19 surveillance programs for variant monitoring. Future commercialization of CLoNeT™ as an in-vitro diagnostic is expected to shift the revenue mix toward product licensing, but the company currently remains a small lab services operation with 1-10 employees and no disclosed revenue.

Name

ID Genomics

Legal name

ID Genomics, Inc.

Website

https://idgenomics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

ID Genomics is a Seattle-based molecular diagnostics lab that provides rapid bacterial identification (CLoNeT™ barcoding), an antibiotic-response surveillance database (BactNeT™), and related genomic and antibiotic susceptibility services to healthcare providers, clinical laboratories, and research institutions.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Molecular diagnostics
• Infectious disease testing
• Microbial identification
• Antibiotic resistance
• Genomic sequencing services

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Laboratory Testing Services: One-time fee-for-service model offering microbial identification, typing, genomic analysis, and antibiotic susceptibility testing. Services include 16S rRNA analysis, MLST typing, S. aureus SPA typing, and SARS-CoV-2 sequencing.
2. Bacterial Strain Collections: Sale of characterized pathogenic bacterial strains for antimicrobial testing. Includes CRE Enterobacteriaceae, ESBL producing Enterobacteriaceae, MDR/XDR Pseudomonas aeruginosa, MRSA, and Enterotoxigenic E. coli strains.
3. Diagnostic Products (CLoNeT™): Future revenue expected from commercialization of CLoNeT™ diagnostic assay for UTI testing. Currently in clinical trial stage with GroupHealth Research Institute partnership.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ID Genomics provides nucleotide sequence-based molecular diagnostics and epidemiologic analysis of microbial pathogens. The company delivers fee-for-service laboratory testing including microbial identification, typing, genomic analysis, and antibiotic susceptibility testing, anchored by two proprietary offerings: CLoNeT™, a rapid (<45 minute) diagnostic assay that assigns proprietary barcodes to infecting bacteria via DNA fingerprinting, and BactNeT™, a surveillance database linking barcodes with antibiotic response data to guide treatment decisions.

Product overview

ID Genomics offers personalized diagnostics for infectious diseases through two core proprietary products and multiple genomic analysis services. The core products are CLoNeT™, a rapid diagnostic test that assigns proprietary barcodes to infecting bacteria in under 45 minutes, and BactNeT™, a big-data surveillance platform that links bacterial samples, barcodes, and clinical antibiotic response data. These are complemented by a suite of genomic analysis services including 16S rRNA Analysis for identifying unknown isolates, 16S rRNA Metagenomics Analysis for culture-free microbial community profiling, ITS Microbiome Testing for fungi, MLST Sequence Typing for fine-resolution species-level identification, S. aureus SPA typing for MRSA strain typing, and Antibiotic Susceptibility Testing using the Kirby-Bauer disc-diffusion method. The company also offers SARS-CoV-2 variant sequencing and a bacterial strain collection for antimicrobial testing.

Differentiator

Problem solved

Functional benefit

Brands

• CLoNeT™: Proprietary rapid diagnostic assay that assigns barcodes to infecting bacteria by identifying fingerprint regions of bacterial DNA. First-generation tests target urinary tract infections (UTIs).
• BactNeT™

Products and services

• SARS-CoV-2 Sequencing Rapid sequencing of key genomic regions of SARS-CoV-2 able to distinguish thousands of circulating variants with potential detection of novel variants. Priced at $29 per sample for healthcare providers and surveillance programs.
• 16S rRNA Analysis DNA analysis of the 16S ribosomal gene to identify the taxonomic identity of unknown microbes, often to the species level, by extracting, amplifying, and sequencing the 16S rRNA gene variable region. For clinical and research laboratories.
• 16S rRNA Metagenomics Analysis A culture-free next-generation sequencing (NGS) method that enables genetic analysis of entire microbial communities' genomes in complex samples by sequencing the V3, V4, and V5 variable regions of the 16S rRNA gene. For research institutions conducting microbiome studies.
• ITS Microbiome Testing – Fungi Detailed genetic analysis of fungal complex samples for microbiome profiling. For research institutions performing fungal community characterization.
• MLST Sequence Typing Multi-locus Sequence Type analysis providing finer resolution microbial identification than 16S by sequencing 5-10 standardized loci to determine the unique Sequence Type (ST), available for up to 100 bacterial species. For clinical and research laboratories tracking, trending, and analyzing isolates.
• S. aureus SPA Typing Inexpensive single-locus typing technique offering subtyping resolution comparable to MLST and PFGE via DNA sequencing of the polymorphic VNTR in the 3' coding region of the Staphylococcus protein A gene (spa) for MRSA strain typing. For clinical and research laboratories.
• Antibiotic Susceptibility Testing Disc-diffusion antibiotic susceptibility testing performed according to CLSI M100S 26th Edition recommendations for any bacterial sample up to biosafety level 2 (BSL-2) using the Kirby-Bauer method. For clinical and research laboratories.
• Bacterial Collections A comprehensive collection of characterized pathogenic bacterial strains including CRE Enterobacteriaceae, ESBL producing Enterobacteriaceae, MDR and XDR Pseudomonas aeruginosa, MRSA, and Enterotoxigenic E. coli (ETEC) available for antimicrobial testing. Sold to clinical and research laboratories.
• CLoNeT™ Rapid diagnostic assay (<45 minutes) that assigns proprietary barcodes to infecting bacteria by identifying fingerprint regions of bacterial DNA to guide antibiotic selection and reduce prescription errors. First-generation tests target urinary tract infections (UTIs). Designed for urgent care settings and healthcare providers.
• BactNeT™ Reference metadata repository linking bacterial samples, IDG's proprietary barcodes, and clinical information with responses to commonly prescribed antibiotics; functions as a growing surveillance database tracking drug-resistant organisms. For clinical and research institutions conducting epidemiological surveillance.

Quantifiable outcome

• Reduces antibiotic prescription errors for UTIs from 25% (1 in 4) to less than 3%
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

One partnership is on record.

• GroupHealth Research InstitutecoreStrategic or Co-development PartnerPartnership with GroupHealth Research Institute in Seattle, WA has permitted early-stage clinical observational trials of first-generation CLoNeT™ in the urgent care setting. This partnership enables real-world validation of the diagnostic technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• BioFire Diagnostics (bioMérieux): A bioMérieux subsidiary and leading molecular diagnostics incumbent for infectious disease panels (FilmArray). Directly comparable to ID Genomics' molecular ID thesis, but with FDA-cleared multiplex panels, established hospital salesforce, and far broader pathogen coverage.
• Cepheid (Danaher): Owner of the GeneXpert system, the dominant rapid molecular diagnostics platform in hospitals and urgent-care settings. Competes head-to-head with CLoNeT™ on time-to-result for UTI and other infectious disease testing, with established FDA-cleared assays and global distribution.
• GenMark Diagnostics (Roche): Now part of Roche, GenMark offers multiplex molecular diagnostic panels (ePlex) for infectious disease detection. Overlaps with ID Genomics' molecular diagnostics thesis as a broader, well-capitalized incumbent in syndromic testing.
• Mobidiag (Hologic): Acquired by Hologic, Mobidiag developed the Amplidiag and Novodiag platforms for molecular diagnostics of infectious diseases and AMR. Comparable on molecular ID + AMR focus, but as part of a much larger diagnostics portfolio post-acquisition.

Direct peers

• T2 Biosystems: Developer of T2 Magnetic Resonance-based rapid diagnostics for bloodstream and other infections. Highly comparable as a small-cap molecular diagnostics company focused on rapid pathogen ID and resistance detection, facing similar commercialization challenges against larger incumbents.
• Accelerate Diagnostics: Commercializes the Accelerate Pheno™ system for rapid ID and antibiotic susceptibility testing directly from positive blood cultures. Closely comparable to ID Genomics' combined ID + AST + surveillance thesis, with similar focus on AMR-driven rapid diagnostics.
• OpGen: Molecular diagnostics company focused on antimicrobial resistance prediction and surveillance using genomic analysis. Comparable product/market overlap with ID Genomics' BactNeT™ surveillance and barcode-based AMR matching approach.
• Specific Diagnostics: Developer of a rapid phenotypic AST system based on volatile organic compound detection. Comparable as a small-cap AMR-focused rapid diagnostics company targeting shorter time-to-AST than traditional methods.
• Selux Diagnostics: Developer of rapid AST technology providing same-shift antibiotic susceptibility results. Directly comparable to ID Genomics' goal of reducing time-to-appropriate-therapy and tackling AMR in clinical settings.
• Q-Linea: Swedish molecular diagnostics company developing the ASTar system for rapid ID/AST directly from clinical samples. Comparable as a small-cap European/US-targeted rapid AST company pursuing the same clinical decision-making window as CLoNeT™.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ID_Genomics
• LinkedInlinkedin.com/company/id-genomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ID Genomics